Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。